John Crowley

President & CEO

Professional Overview
John Crowley is a seasoned executive with extensive experience in the biotechnology and pharmaceutical industries. As the President and CEO of the Biotechnology Innovation Organization (BIO), he leverages his deep industry expertise to drive innovation and advocate for policies that support the development of life-saving therapies.

Experience Summary

Current Role
In his current role as President and CEO of BIO, Mr. Crowley leads the organization's mission to advance the biotechnology industry and promote the development of innovative products that improve human health and the environment. Under his leadership, BIO has played a key role in shaping regulatory policies, fostering collaboration, and championing the interests of its member companies.

Career Progression
Prior to joining BIO, Mr. Crowley served as the Executive Chairman of Amicus Therapeutics, a leading rare disease biotechnology company. During his tenure, he oversaw the company's strategic direction and the development of several groundbreaking therapies. Before that, he held leadership positions at Orexigen Therapeutics, Genzyme, Novazyme Pharmaceuticals, and Bristol-Myers Squibb, where he demonstrated his ability to drive growth, navigate complex regulatory environments, and bring innovative products to market.

Mr. Crowley also served as an Officer in the US Navy Reserve, leveraging his expertise to support national security initiatives.

Academic Background
Mr. Crowley holds a Juris Doctor degree from the University of Notre Dame Law School, where he graduated with distinction.

Areas of Expertise

• Biotechnology and pharmaceutical industry

• Rare disease drug development

• Regulatory affairs and policy

• Strategic leadership and business development

• Mergers and acquisitions

• Military and government relations

Professional Impact
Throughout his career, Mr. Crowley has been recognized for his contributions to the biotechnology industry. He has played a pivotal role in advancing therapies for rare and genetic diseases, and has been a vocal advocate for policies that support medical innovation and patient access to life-saving treatments.

Conclusion
With his extensive experience, deep industry knowledge, and proven track record of success, John Crowley is well-positioned to lead the Biotechnology Innovation Organization and drive the continued growth and advancement of the biotechnology sector.